Rocket Pharmaceuticals announces clearance of IND for RP-A501 gene therapy for Danon disease
RP-A501 is the Company’s first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a collaboration with the University of